News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “Global Antibody Drug Conjugate Market Outlook 2018”, the global market for ADCs is estimated to reach approximately US$ 3 Billion by 2018, growing at a CAGR of around 55% over 2014-2018. The market presently consists of only two ADCs namely, ADCETRIS and Kadcyla. However, these ADCs are also being incorporated with different therapies in various phases of clinical trials, an indication that the coming years will witness stupendous growth.
 
With the significant advancement in the linking technologies many players are entering into the pool of ADC research and development. Further, in order to cash in on this new technology, pharma giants are indulging in strategic moves such as collaborations, mergers and acquisitions. Most of these moves are being made in order to combine technologies and capabilities from other companies with inherent ones for the development of ADCs. Taking into consideration the present scenario and growth opportunities ADC market is anticipated to witness an impressive progression.
 
Research Analysis & Highlights
 
This report is spread over 60 pages and provides an in-depth research and rational analysis of the current status and future prospect of the Antibody Drug Conjugate market. The report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved.
 
The report also provides an insight into the key ADCs that are currently in pipeline. A brief analysis on the types of ADCs is being done on the basis of types of drug used, clinical phases and cancers targeted. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided.
 
At the end, major players of ADC market have been discussed. A brief business overview of every player has been provided alongwith their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM667.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm